A Randomized, Double-blind, Multicenter Study to Assess the Efficacy and Safety of a 6 Month Oral Treatment With the Chymase Inhibitor BAY 1142524 at a Dose of 25 mg BID in Comparison to Placebo on Top of Standard of Care in Patients With Type II Diabetes and a Clinical Diagnosis of Diabetic Kidney Disease
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Bayer
- 入组人数
- 152
- 试验地点
- 27
- 主要终点
- Change in urinary albumin to creatinine ratio (UACR)
研究概览
简要总结
The purpose of the trial is the analysis of safety and efficacy of the chymase inhibitor BAY1142524 at a dose of 25 mg BID in comparison to placebo using a 6 months treatment period in type II diabetic patients with a clinical diagnosis of diabetic kidney disease. BAY1142524 or placebo will be given on top of evidence-based standard of care for diabetic kidney disease. Primary objective is the analysis of first signs of efficacy as determined by favourable changes in urinary albumin creatinine ratio. Secondary objective is the analysis of safety and tolerability as evidenced by the incidence and severity of adverse events. 64 valid patients have to complete treatment with verum and 32 valid patients have to complete treatment with placebo.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 79 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with Type 2 Diabetes Mellitus and a clinical diagnosis of diabetic kidney disease (DKD) (as judged by the investigator) who have finished their up-titration with an angiotensin receptor blocker (ARB) or an ACEI (angiotensin-converting enzyme inhibitor) to their maximum tolerated dose at least 3 months prior to the screening visit, whereby the maximum tolerated dose has to be at least as high as the minimal recommended dose of an ARB or ACEI according to local and/or international guidelines. Patients have to be treated with an ARB or ACEI, but not with both simultaneously, without any adjustments to this therapy for at least 4 weeks prior to the screening visit.
- •UACR >50 mg/g and <3000 mg/g in 2 out of 3 consecutive morning void samples at the screening and the baseline visit
- •estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73 m*2 and <90 mL/min/1.73 m*2 (Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI]) at the screening visit and the baseline visit
排除标准
- •Non-DKD if it is the main diagnosis contributory to chronic kidney disease (CKD), as judged by the investigator
- •Known bilateral clinical relevant renal artery stenosis (>75%)
- •New York Heart Association (NYHA) Class IV
- •Acute kidney injury or dialysis within the last 3 months before the screening visit
- •Renal replacement therapy during study conduct
- •Renal allograft in place or a scheduled kidney transplant during study conduct
- •Stroke, transient ischemic cerebral attack, acute coronary syndrome, or hospitalization for heart failure in the last 3 months prior to screening visit
- •Clinically relevant hepatic dysfunction
- •Uncontrolled hypertension as evidenced by systolic blood pressure >160 mmHg, diastolic blood pressure >100 mmHg (mean of triplicate values at the screening or baseline visit)
研究组 & 干预措施
Fulacimstat (BAY1142524)
Patients have to have a clinical diagnosis of diabetic kidney disease and have to be treated with standard of care for this condition
干预措施: Fulacimstat (BAY1142524) (Drug)
Placebo
Patients have to have a clinical diagnosis of diabetic kidney disease and have to be treated with standard of care for this condition
干预措施: Placebo (Drug)
结局指标
主要结局
Change in urinary albumin to creatinine ratio (UACR)
时间窗: Baseline and at 6 months
The ratio of albumin to creatinin will be determined in first morning void urine at baseline (before treatment start) and after 6 months of treatment
次要结局
- Number of patients with serious adverse events(From first intake of study drug up to 3 days after last administration of study drug)
- Number of patients with treatment-emergent adverse event(From first intake of study drug up to 3 days after last administration of study drug)